Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Amiodarone-induced pulmonary toxicity

Bartosz Hudzik and Lech Polonski
CMAJ October 16, 2012 184 (15) E819; DOI: https://doi.org/10.1503/cmaj.111763
Bartosz Hudzik
Third Department of Cardiology, Silesian Center for Heart Disease, Medical University of Silesia, Zabrze, Poland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bartekh@mp.pl
Lech Polonski
Third Department of Cardiology, Silesian Center for Heart Disease, Medical University of Silesia, Zabrze, Poland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

A 74-year-old man, a current smoker, presented with shortness of breath and a dry cough. He had a history of ventricular tachyarrhythmia treated with amiodarone (200 mg/d for 6 years), a previous myocardial infarction and coronary artery bypass surgery.

On examination, bilateral crackles could be heard on inspiration. Clubbing was absent. Radiography of the patient’s chest showed diffuse interstitial and alveolar opacities, and echocardiography showed mild dysfunction of the left ventricle with an ejection fraction of 48%. His arterial blood gases were normal, but pulmonary function tests showed restriction with a reduced carbon monoxide–diffusing capacity (45% of predicted). High-resolution computed tomography showed signs consistent with amiodarone-induced interstitial pulmonary fibrosis (Figure 1). Amiodarone was stopped, and an alternate antiarrythmic agent was used. The patient’s symptoms improved.

Figure 1:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1:

High-resolution computed tomography images of the chest of a 74-year-old man with dyspnea and cough. Bilateral, ground-glass opacities (white arrows), high-attenuation infiltrates (black arrows), traction bronchiectases (white arrowheads) and honeycombing (black arrowheads) suggest amiodarone-induced pulmonary toxicity, in addition to emphysema (white asterisk).

Amiodarone is associated with a wide range of adverse effects, including pulmonary toxicity. With long-term use, the prevalence of such toxicity varies between 5% and 15%.1 The spectrum of disease ranges from mild chronic or subacute lung disease to rapidly progressing acute airway and lung disease, including acute respiratory distress syndrome with high mortality.2 Risk factors include a high cumulative dose of the drug (≥ 100 g), a high daily dose (≥ 400 mg), long-lasting therapy (≥ 2 mo), pre-existing lung disease and older age.1 Lower doses (≤ 200 mg/d) have also been associated with serious pulmonary toxicity.1,3

Symptoms can include progressive dyspnea, dry cough, malaise and pleuritic chest pain. Bilateral crackles may be heard on examination. Radiographic features can include interstitial or alveolar (ground-glass) shadows that may be localized or diffuse, and traction bronchiectases with a honeycombing pattern (Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.111763/-/DC1).1–3 Pulmonary function tests may show reduced carbon monoxide–diffusing capacity. Stopping amiodarone therapy is the treatment of choice. Despite a lack of controlled studies, experts suggest that corticosteroids may help patients with acute disease, hypoxemia and substantial involvement seen on imaging.1–3 The prognosis is usually good in cases of chronic or subacute disease. Because pulmonary fibrosis may develop, a lung biopsy is suggested if symptoms do not improve within 1 or 2 months of drug withdrawal.1

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

References

  1. ↵
    1. Schwaiblmair M,
    2. Berghaus T,
    3. Haeckel T,
    4. et al
    . Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect? Clin Res Cardiol 2010;99:693–700.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Papiris SA,
    2. Triantafillidou C,
    3. Kolilekas L,
    4. et al
    . Amiodarone: review of pulmonary effects and toxicity. Drug Saf 2010;33:539–58.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Wolkove N,
    2. Baltzan M
    . Amiodarone pulmonary toxicity. Can Respir J 2009;16:43–8.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 184 (15)
CMAJ
Vol. 184, Issue 15
16 Oct 2012
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Amiodarone-induced pulmonary toxicity
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Amiodarone-induced pulmonary toxicity
Bartosz Hudzik, Lech Polonski
CMAJ Oct 2012, 184 (15) E819; DOI: 10.1503/cmaj.111763

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Amiodarone-induced pulmonary toxicity
Bartosz Hudzik, Lech Polonski
CMAJ Oct 2012, 184 (15) E819; DOI: 10.1503/cmaj.111763
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Amiodarone-induced interstitial pneumonitis
  • Google Scholar

More in this TOC Section

  • “Superscan” in diffusion-weighted imaging with background body suppression magnetic resonance imaging
  • Using intranasal corticosteroids
  • Langerhans cell histiocytosis in a 5-month-old baby
Show more Practice

Similar Articles

Collections

  • Sections
    • Clinical Images
  • Topics
    • Respiratory medicine
    • Drugs: adverse reactions

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire